Glenmark Life Sciences Q4 PAT down 5.52% amid high input cost inflation

21 Apr 2022 , 12:23 AM

Glenmark Life Sciences Ltd reported 10.04% growth yoy in total revenues for the Mar-22 quarter on consolidated basis at Rs514.06cr. On a sequential basis, the revenues were lower for the quarter by -1.62%.

For FY22, revenues from the generic API segment increased by 12.1% while the CDMO business saw revenues grow by 12.4%. While regulated market revenues grew 21.4%, the emerging market revenues fell by -6.3%.

The board has recommended a final dividend of Rs.10.50/share, taking the total dividend to Rs.21.

The consolidated net profit for Q4 was down -5.52% to Rs98.90cr, while the profits were lower by -4.64% on a sequential basis.

While input costs were an issue, the emerging markets business also took a dip on profits. EBITDA margins at 28.7% in Q4 were up 10 bps on a yoy basis but 770 bps lower on a sequential basis.

Ratio of regulated to emerging markets is 72:28. Net margins for stood at 19.24% in Mar-22 quarter compared to 22.41% in Mar-21. The net profit margins were also lower by 611 basis points on a sequential basis.

Financial highlights for Mar-22 compared yoy and sequentially

	Glenmark Life Sciences
Rs in Crore	Mar-22	Mar-21	YOY	Dec-21	QOQ
Total Income (Rs cr)	₹ 514.06	₹ 467.16	10.04%	₹ 522.50	-1.62%
Net Profit (Rs cr)	₹ 98.90	₹ 104.68	-5.52%	₹ 103.71	-4.64%
Diluted EPS (Rs)	₹ 8.07	₹ 9.71		₹ 8.65
Net Margins	19.24%	22.41%		19.85%